[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
November 26, 1960

Therapeutic Spectrum of Uracil-Mustard, A New Oral Antitumor DrugWith Special Reference to the Effects of Small Dosage in Lymphomas, Chronic Leukemias, and Ovarian Carcinoma

Author Affiliations

Orange, Calif.; Duarte, Calif.; Orange, Calif.

From the City of Hope Medical Center, Duarte, Calif., and Orange County General Hospital, Orange, Calif. Dr. Miller is presently Director of the Neoplastic Division, Maimonides Hospital, Brooklyn, N. Y. Dr. Opfell is Chairman of the Department of Medicine, Orange County General Hospital, Orange, Calif.

JAMA. 1960;174(13):1702-1705. doi:10.1001/jama.1960.03030130030008

One hundred and thirty patients with various neoplastic disorders were treated with uracil-mustard (U-8344), a new oral alkylating agent with a therapeutic spectrum similar to that of other mustard analogues. This agent was especially effective in treatment of lymphomas and chronic leukemias. Occasionally solid tumors, notably ovarian carcinoma, responded. Advantages of uracil-mustard over other similar agents are: (1) the small dosage required to obtain beneficial results; (2) uniform tolerability; and (3) simplicity of the regimen. With judicious administration long-term therapy may be carried out with continued benefit. The study suggested that the drug may be of value when other alkylating agents have failed.